Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines

• Computational tool improves recombinant virus design efficiency and yield.
• This innovative in-house development is a key component of Transgene’s INTV^[1] platform.
• Poster to be presented at ESMO-AI 2025

Strasbourg, France, November 6, 2025, 8:30 a.m.  CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer today announced it will present a poster on its proprietary VacDesignR® computational tool at the upcoming ESMO AI & Digital Oncology 2025 conference, held in Berlin, Germany, from 12-14 November 2025.

The presentation will highlight how VacDesignR® streamlines the design and production of recombinant Modified Vaccinia Ankara (MVA)-based vectors, enabling faster and more reliable manufacturing of individualized neoantigen therapeutic vaccines (INTV).

The individualized immunotherapies developed through the myvac® platform, currently being evaluated in a Phase I/II clinical trial (NCT04183166), are based on an MVA viral vector and their design already leverages the VacDesignR® tool.

Developed in-house, VacDesignR® is a computational design engine that optimizes recombinant plasmid architecture for MVA vectors, a core component of Transgene’s myvac® platform. By minimizing unwanted homologous recombination and intelligently selecting peptide sequences for cassette assembly, VacDesignR® significantly improves production reliability and vector quality.

Future iterations of VacDesignR® will incorporate AI-based components to further improve performance and scalability, supporting Transgene’s strategy to accelerate production timelines for individualized therapeutic vaccines, including its lead candidate TG4050 designed to treat HPV-negative head and neck cancers following surgery and adjuvant therapy.

“Participating at the first edition of the ESMO AI & Digital Oncology meeting highlights Transgene’s pioneering role in combining viral vector-based individualized cancer vaccines with its vaccine design tool to optimize product performance and redefine the future of oncology treatment”, commented Maurizio Ceppi, Chief Scientific Officer of Transgene.

Title of the abstract: “VacDesignR®: a computational tool to optimize viral-based individualized neoantigen therapeutic vaccine production”

Title of the poster: “VacDesignR®: a tool for optimizing recombinant poxvirus vaccine production”

• Poster and Abstract number: 385P
• Session: Drug development
• Date: November 12, 2025
• Author: B. Grellier

The poster presentation will take place on November 12 at ESMO-AI conference and will be available that day on Transgene’s website.

VacDesignR® is a computer-assisted method protected through patent and patent applications derived from WO2021/130210.

1 Individualized Therapeutic Neoantigen Vaccine

[1] Individualized Therapeutic Neoantigen Vaccine